Neofordex: Withdrawal of the marketing authorisation application



On 17 July 2014, Laboratories CTRS officially notified the Committee for Medicinal Products for Human Use (CHMP) that it wishes to withdraw its application for a marketing authorisation for Neofordex, for the treatment of multiple myeloma.

  • List item

    Questions and answers on the withdrawal of the marketing-authorisation application for Neofordex (PDF/62.37 KB)

    First published: 25/07/2014
    Last updated: 20/11/2014

  • Key facts

    Product number
    International non-proprietary name (INN) or common name
    • dexamethasone
    Active substance
    • dexamethasone
    Date of withdrawal
    Company making the application
    Laboratoires CTRS - Boulogne Billancourt
    Withdrawal type
    Initial authorisation

    All documents

    Related information on withdrawals

    A question-and-answer (Q&A) document provides a summary of the CHMP's evaluation of the medicine at the time of the withdrawal of the application, and includes a link to the company's formal withdrawal letter.

    An assessment report is published when the application is withdrawn after the first stage of the CHMP's evaluation is completed ('day 120').

    How useful was this page?

    Add your rating